General Information
Revision date
2003-08-12
Product name
BL 154 75W-90 TRANSMISSION OIL
Emergency telephone
Assistance DUMONDE 425-806-0948
Icons in SDS
Company Information
company name
DUMONDE DESIGN GROUP INC
Section 2
SECTION 2: Hazards identification
NFPA Rating -------------------------------- EMERGENCY OVERVIEW
Appearance/Odor
Pale liquid Slight Hydrocarbon Odor
Health hazards
No known immediate health hazards. High-pressure injection under the skin may cause serious damage.
Physical hazards
No known physical hazards
NFPA Ratings
Health, Fire, Reactivity) 0, 1, 0
Hazard statements
Least - 0 Slight - I Moderate - 2 High - 3 Extreme - 4 Inhalation: Inhalation of vapors (generated at high temperatures only) or oil mist may cause mild irritation of the nose, throat, and respiratory tract. Eye Irritation: Lubricating oils are generally considered no more than minimally irritating to the eyes. Skin Contact: Lubricating oils are generally considered no more than minimally irritating to the skin. Prolonged and repeated contact may result in defatting and drying of the skin that may cause various skin disorders such as dermatitis, folliculitis or oil acne. Release of the material during high-pressure applications may result in injection under the skin causing possible extensive tissue damage which is difficult to heal. Ingestion: Lubricating oils are generally no more than slightly toxic if swallowed.
Other Health Effects
The International Agency for Research on Cancer (IARC) has determined there is sufficient evidence for the carcinogenicity in experimental animals of used gasoline motor oils. Handling procedures and safety precautions in the MSDS should be followed to minimize exposure to the used product. Signs and Symptoms: Irritation as noted above. Local necrosis is evidenced by delayed onset of pain and tissue damage a few hours following injection.
Medical Conditions Generally Aggravated by Exposure
Pre-existing eye, skin and respiratory disorders may be aggravated by exposure to this product. For additional health information, refer to section 11. -------------------------------------